Cost Is One of the Biggest Barriers to Brexafemme Kit Adherence

You've determined that Brexafemme Kit (Ibrexafungerp) is the right treatment for your patient's vulvovaginal candidiasis (VVC) or recurrent VVC. But when the pharmacy quotes a cash price of $450–$600 per treatment course, the conversation shifts from clinical to financial. And for patients on monthly RVVC prevention (six courses over six months), the potential annual cost without coverage can exceed $3,000.

Medication cost is a well-documented adherence barrier. Patients who can't afford their prescriptions simply don't fill them. This guide provides a practical framework for helping your patients access Brexafemme Kit at a manageable cost — or identify appropriate alternatives when the numbers don't work.

What Patients Are Actually Paying

Understanding the cost landscape helps you set realistic expectations during the prescribing conversation:

Without Insurance

• Cash price: $450–$600 per treatment course (four 150 mg tablets)
• RVVC prevention (6 months): $2,700–$3,600 total without assistance
• No generic available: Ibrexafungerp remains brand-only as of 2026

With Commercial Insurance

• Coverage: Many commercial plans cover Brexafemme Kit, but frequently require prior authorization or step therapy (typically Fluconazole first)
• Copay range: Varies widely — from $30–$75 with good coverage to several hundred dollars on high-deductible plans
• Prior authorization: Be prepared to document Fluconazole failure or intolerance, recurrent infection history, and culture results if available

With Medicare Part D

• Coverage: Some Part D plans include Brexafemme Kit, though tier placement varies
• 2026 benefit: The $2,000 annual out-of-pocket cap limits total yearly medication costs for Part D enrollees
• Donut hole considerations: High-cost brand medications like Brexafemme Kit can accelerate patients through the coverage gap

Manufacturer Savings Programs

Copay Assistance Card

Scynexis offered a copay assistance savings card for eligible commercially insured patients that could reduce out-of-pocket costs to as low as $30 per treatment course. Key details:

• Eligibility: Commercially insured patients (not eligible for those on government insurance including Medicare, Medicaid, or Tricare)
• How to enroll: Call 1-844-431-9894 or visit the manufacturer's website
• Current status: Availability may be affected by the drug's temporarily unavailable status and the NDA transfer to GSK. Contact the number above to verify current program status.

When prescribing Brexafemme Kit, proactively providing the copay card information at the point of prescribing significantly increases the likelihood that patients will fill the prescription.

Patient Assistance Program

For uninsured or underinsured patients who meet financial hardship criteria:

• Scynexis program: Previously offered assistance for qualifying patients
• GSK For You: With the NDA transfer to GSK completed in November 2025, patients should check GSK's patient assistance programs
• Contact: 1-844-431-9894 for current information on both programs

Assist your patients by providing a letter of medical necessity when requested by assistance programs. Document the clinical rationale for Brexafemme Kit over alternatives.

Coupon and Discount Cards

Third-party prescription discount programs can sometimes reduce costs for uninsured or underinsured patients. Direct patients to:

• GoodRx — Search for Brexafemme Kit pricing at nearby pharmacies and access discount coupons
• SingleCare — May offer discounted pricing at participating pharmacies
• RxSaver — Compare prices across pharmacy chains
• Optum Perks — Discount card accepted at many pharmacies

Important caveats for providers:

• Discount cards cannot be combined with insurance copays
• Pricing varies significantly by pharmacy — the same card may save $50 at one location and $200 at another
• Specialty pharmacies sometimes offer better pricing for brand medications than retail chains

For a comprehensive list of savings options, refer patients to our patient savings guide.

Generic Alternatives and Therapeutic Substitution

When Brexafemme Kit is not financially feasible, consider these evidence-based alternatives:

First-Line: Fluconazole (Diflucan)

• Cost: $3–$15 (generic)
• Indication: Acute VVC (single 150 mg dose); RVVC prevention (weekly or monthly dosing off-label)
• Considerations: Most insurance plans require step therapy with Fluconazole before covering Brexafemme Kit. If the patient has documented Fluconazole failure or resistance, this strengthens the prior authorization for Brexafemme Kit.

Oteseconazole (Vivjoa)

• Cost: Brand-name only (comparable cost range)
• Indication: FDA-approved for RVVC prevention
• Considerations: Different mechanism (azole class), different dosing schedule (daily induction then weekly). Also contraindicated in pregnancy. May have different formulary placement with some payors.

OTC Topical Options

• Miconazole (Monistat): $10–$20, available OTC in 1-day, 3-day, and 7-day regimens
• Clotrimazole: $8–$15 OTC
• Considerations: Appropriate for uncomplicated acute VVC but not suitable for RVVC prevention. Patient preference and adherence should be factored in — some patients strongly prefer oral over topical treatment.

When to Advocate for Brexafemme Kit Despite Cost

Certain clinical scenarios warrant pushing for coverage:

• Documented Fluconazole resistance on culture
• Recurrent infections despite Fluconazole prophylaxis
• Azole intolerance or allergy
• Non-albicans Candida species with reduced azole susceptibility
• Patient preference for one-day oral treatment (adherence consideration)

Building Cost Conversations Into Your Workflow

At the Point of Prescribing

1. Check formulary status before writing the prescription. Most EHR systems include formulary look-up tools.
2. Discuss cost proactively. Don't wait for the patient to discover the price at the pharmacy. Say: "This medication can be expensive without coverage. Let me check what your plan covers and what savings options are available."
3. Provide the copay card information at the visit — don't assume the pharmacy will mention it.
4. Document step therapy completion in your notes. If the patient has tried Fluconazole, note the dates, doses, and outcomes clearly. This streamlines prior authorization.

When Prior Authorization Is Required

• Include culture results showing Candida species and susceptibility when available
• Document the number and frequency of VVC episodes (especially for RVVC)
• Note prior treatment failures with dates and specifics
• Provide a clear letter of medical necessity
• Consider peer-to-peer review if initial authorization is denied — approval rates increase significantly after provider-to-provider discussion

At Follow-Up

• Ask if the patient was able to fill the prescription
• If not, troubleshoot — was it cost, availability, or something else?
• For RVVC patients on monthly dosing, confirm they're filling each month's supply
• Reassess the treatment plan if cost is creating adherence gaps

Leverage Your Care Team

• Medical assistants and nurses: Can verify insurance coverage and initiate prior authorizations
• Social workers: Can assist with patient assistance program applications
• Pharmacists: Can run real-time benefit checks and suggest therapeutic alternatives at lower tier placement

Availability Considerations

As of early 2026, Brexafemme Kit is temporarily unavailable. The NDA transfer from Scynexis to GSK was completed in November 2025, and no confirmed return date has been announced. For the latest availability updates and to help patients locate remaining stock, visit Medfinder for Providers.

Also see our provider guide to finding Brexafemme Kit in stock for sourcing strategies.

Final Thoughts

The gap between prescribing the right medication and the patient actually taking it often comes down to cost. For a brand-only medication like Brexafemme Kit at $450–$600 per course, proactive cost navigation isn't optional — it's part of quality care.

Build cost conversations into your workflow, provide savings resources at the point of prescribing, and document clinical rationale thoroughly for prior authorizations. When Brexafemme Kit isn't financially accessible, work with your patients to find the best alternative that balances clinical efficacy with affordability.

For more provider resources on Brexafemme Kit, visit Medfinder for Providers.